LFST · Lifestance Health Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $403.48M | - | $363.81M | $345.31M | $332.97M | - | $312.72M | $312.33M | $300.44M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $100.33M | - | $95.61M | $97.38M | $94.43M | - | $85.27M | $95.15M | $88.93M | - |
| Total Operating Expenses | $381.19M | - | $356.40M | $348.26M | $331.37M | - | $312.68M | $328.28M | $317.21M | - |
| D&A | $10.37M | - | $10.34M | $10.64M | $10.29M | - | $10.41M | $10.13M | $10.02M | - |
| Operating Income | $22.28M | - | $7.41M | ($2.95M) | $1.60M | - | $47.0K | ($15.95M) | ($16.77M) | - |
| Interest Expense | $1.79M | - | $2.81M | $2.90M | $3.07M | - | $5.41M | $5.82M | $5.90M | - |
| Income Tax | $5.52M | - | $3.50M | ($2.15M) | ($2.18M) | - | $575.0K | $656.0K | $363.0K | - |
| Net Income | $14.24M | - | $1.08M | ($3.79M) | $709.0K | - | ($5.96M) | ($23.28M) | ($21.10M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $194.80M | $248.64M | $203.90M | $188.93M | $134.34M | $154.57M | $102.61M | $86.97M | $49.45M | $78.82M |
| Accounts Receivable | $122.92M | $95.71M | $121.07M | $129.48M | $140.37M | $131.80M | $158.16M | $167.22M | $175.94M | $125.41M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.29M | $6.12M | $12.21M | $7.79M | $7.42M | $7.24M | $7.28M | $9.97M | $11.94M | $7.05M |
| Current Assets | $355.91M | $416.20M | $360.38M | $358.85M | $304.63M | $312.51M | $287.02M | $277.75M | $244.12M | $225.73M |
| Total Assets | $2.15B | $2.20B | $2.15B | $2.15B | $2.10B | $2.12B | $2.11B | $2.12B | $2.11B | $2.11B |
| Current Liabilities | $239.73M | $251.96M | $228.56M | $242.28M | $207.38M | $228.89M | $217.51M | $227.66M | $207.46M | $202.87M |
| Long-term Debt | $262.46M | $265.93M | $269.39M | $272.86M | $276.32M | $279.79M | $279.06M | $279.46M | $279.87M | $280.29M |
| Total Liabilities | $668.47M | $682.92M | $656.23M | $672.88M | $647.57M | $672.01M | $670.85M | $689.32M | $677.32M | $681.04M |
| Stockholders' Equity | $1.48B | $1.52B | $1.49B | $1.47B | $1.46B | $1.45B | $1.44B | $1.43B | $1.43B | $1.43B |
| Retained Earnings | ($794.38M) | ($808.63M) | ($820.29M) | ($821.37M) | ($817.58M) | ($818.29M) | ($811.18M) | ($805.22M) | ($781.94M) | ($760.85M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $33.11M | - | - | - | ($3.09M) | - | - | - | ($21.84M) | - |
| Investing Cash Flow | ($13.91M) | - | - | - | ($7.17M) | - | - | - | ($5.10M) | - |
| Financing Cash Flow | ($73.04M) | - | - | - | ($9.97M) | - | - | - | ($2.43M) | - |
| CapEx | $10.77M | - | - | - | $7.17M | - | - | - | $5.10M | - |
| Free Cash Flow | $22.34M | - | - | - | ($10.26M) | - | - | - | ($26.94M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 5.5% | - | 2.0% | -0.9% | 0.5% | - | 0.0% | -5.1% | -5.6% | - |
| EBITDA margin | 8.1% | - | 4.9% | 2.2% | 3.6% | - | 3.3% | -1.9% | -2.2% | - |
| Net margin | 3.5% | - | 0.3% | -1.1% | 0.2% | - | -1.9% | -7.5% | -7.0% | - |
| Free cash flow margin | 5.5% | - | - | - | -3.1% | - | - | - | -9.0% | - |
| FCF / Net income | 1.57 | - | - | - | -14.47 | - | - | - | 1.28 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 24.9% | - | 26.3% | 28.2% | 28.4% | - | 27.3% | 30.5% | 29.6% | - |
| Effective tax rate | 27.9% | - | 76.4% | - | - | - | - | - | - | - |
| Return on assets | 0.7% | - | 0.1% | -0.2% | 0.0% | - | -0.3% | -1.1% | -1.0% | - |
| Return on equity | 1.0% | - | 0.1% | -0.3% | 0.0% | - | -0.4% | -1.6% | -1.5% | - |
| Return on invested capital | 0.9% | - | 0.2% | -0.1% | 0.1% | - | 0.0% | -0.7% | -0.8% | - |
| Liquidity | ||||||||||
| Current ratio | 1.48 | 1.65 | 1.58 | 1.48 | 1.47 | 1.37 | 1.32 | 1.22 | 1.18 | 1.11 |
| Quick ratio | 1.48 | 1.65 | 1.58 | 1.48 | 1.47 | 1.37 | 1.32 | 1.22 | 1.18 | 1.11 |
| Cash ratio | 0.81 | 0.99 | 0.89 | 0.78 | 0.65 | 0.68 | 0.47 | 0.38 | 0.24 | 0.39 |
| Leverage | ||||||||||
| Debt / Equity | 0.18 | 0.17 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.20 | 0.20 | 0.20 |
| Debt / Assets | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 |
| Debt / EBITDA | 8.04 | - | 15.17 | 35.49 | 23.23 | - | 26.69 | - | - | - |
| Interest coverage | 12.4x | - | 2.6x | -1.0x | 0.5x | - | 0.0x | -2.7x | -2.8x | - |
| Equity multiplier | 1.45 | 1.45 | 1.44 | 1.46 | 1.44 | 1.46 | 1.47 | 1.48 | 1.47 | 1.48 |
| Liabilities / Assets | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.32 | 0.32 | 0.33 | 0.32 | 0.32 |
| Efficiency | ||||||||||
| Asset turnover | 0.19 | - | 0.17 | 0.16 | 0.16 | - | 0.15 | 0.15 | 0.14 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 111d | - | 121d | 137d | 154d | - | 185d | 195d | 214d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.7x | - | 1.4x | 1.4x | 1.8x | - | 1.9x | 1.3x | 1.6x | - |
| P / S | 6.2x | - | 5.9x | 5.8x | 7.8x | - | 8.5x | 6.0x | 7.7x | - |
| EV / EBITDA | 79.2x | - | 124.2x | 271.0x | 230.7x | - | 271.5x | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 21.2% | - | 16.3% | 10.6% | 10.8% | - | 19.0% | 20.3% | 18.9% | - |
| Revenue CAGR (3y) | 16.9% | - | 18.7% | 18.1% | 17.9% | - | 45.3% | 24.8% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 1289.3% | - | 15666.0% | 81.5% | - | - | - | 67.1% | 50.8% | - |
| Net income growth (YoY) | 1908.9% | - | - | 83.7% | - | - | 90.3% | 48.8% | 38.4% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 61.9% | - | - | - | -72.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1.4% | 5.2% | 3.9% | 3.1% | 2.0% | 1.2% | -1.2% | -4.3% | -5.1% | -5.9% |
Peer comparison
Same SIC group: Services-Health Services
Comparing LifeStance Health Group against the 5 most active filers in the same SIC group.